Cargando…

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer

PURPOSE: The outcome of the luminal oestrogen receptor-positive (ER +) subtype of breast cancer (BC) is highly variable and patient stratification needs to be refined. We assessed the prognostic significance of oestrogen-regulated solute carrier family 39 member 6 (SLC39A6) in BC, with emphasis on E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Althobiti, Maryam, El-sharawy, Khloud A., Joseph, Chitra, Aleskandarany, Mohammed, Toss, Michael S., Green, Andrew R., Rakha, Emad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505289/ https://www.ncbi.nlm.nih.gov/pubmed/34453638 http://dx.doi.org/10.1007/s10549-021-06336-y

Ejemplares similares

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
por: Joseph, Chitra, et al.
Publicado: (2020)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
por: Green, Andrew R., et al.
Publicado: (2016)

The molecular diversity of Luminal A breast tumors
por: Ciriello, Giovanni, et al.
Publicado: (2013)

The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer
por: Kariri, Yousif A., et al.
Publicado: (2022)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
por: Miligy, Islam M., et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Correction: The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
por: Miligy, Islam M., et al.
Publicado: (2020)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2017)

The intra-tumoural stroma in patients with breast cancer increases with age
por: Vangangelt, Kiki M. H., et al.
Publicado: (2019)

Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
por: Mirza, Sameer, et al.
Publicado: (2013)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5mjhkljv13s2hhqpsetcs33ibu